Insulet (PODD) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ResMed (RMD) has outperformed Insulet (PODD) over the past year, losing 6.0% versus a loss of 59.8%. Over five years, RMD leads with a -6.2% price change compared with -54.9% for PODD. ResMed is the larger company by market cap ($33.14 billion vs $9.24 billion), about 3.6 times the size, while Insulet is growing revenue faster (+30.7% vs +9.9%).
On valuation, Insulet trades at a lower forward P/E (16.8x vs 17.8x for ResMed). ResMed pays a dividend yielding 1.04%, while Insulet does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 9.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PODD | RMD |
|---|---|---|
| Share price | $133.17 | $235.63 |
| Market cap | $9.24B | $33.14B |
| 1-day change | -2.96% | -0.53% |
| YTD return | -53.15% | -2.18% |
| 1-year return | -59.79% | -6.03% |
| 5-year return | -54.92% | -6.20% |
| P/E ratio (TTM) | 21.76 | 21.46 |
| Forward P/E | 16.83 | 17.82 |
| EPS (TTM) | $6.12 | $10.98 |
| Dividend yield | 0.00% | 1.04% |
| Annual dividend | $0.00 | $2.46 |
| Revenue (latest FY) | $2.71B | $5.65B |
| Revenue growth (YoY) | +30.73% | +9.85% |
| Net income (latest FY) | $247.10M | $1.52B |
| Gross margin | 71.63% | 61.06% |
| Operating margin | 17.50% | 33.37% |
| Net margin | 9.12% | 26.94% |
| 52-week high | $342.13 | $277.67 |
| 52-week low | $126.40 | $180.27 |
| Distance from 52-week high | -61.08% | -15.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +33.60% | +12.18% |
| Average volume | 1.61M | 1.30M |
| Shares outstanding | 69.37M | 140.66M |
| Employees | 5,400 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ResMed is about 3.6 times larger than Insulet by market value ($33.14B vs $9.24B).
- RMD has outperformed PODD by 53.8 percentage points over the past year.
- ResMed offers a meaningfully higher dividend yield (1.04% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +9.85%).
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
PODD vs RMD FAQ
Which is bigger, Insulet or ResMed?
ResMed (RMD) is larger, with a market capitalization of $33.14B compared with $9.24B for Insulet (PODD).
Which stock has performed better over the past year, PODD or RMD?
RMD returned -6.03% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PODD or RMD?
RMD has the lower trailing P/E at 21.5, versus 21.8 for PODD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Insulet or ResMed?
ResMed pays a dividend yielding 1.04%, while Insulet does not currently pay a regular dividend.
Are Insulet and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.